Tuesday, February 14, 2017 1:49:34 PM
Tobira was acquired by Allergan for a minimum of $28.35 per share, or $1.13B and this can increase to $1.965B if they meet their goals.
Tobira announced one year results on a Phase 2 NASH study at the same time as their deal with Allergan-the study is going to go for two years.
Based on this CNAT has to be worth at least 3-4X the current market cap today, why it is at $5 is beyond me but I have taken advantage of the buying opportunity.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM